logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Cholesterol lowering and the use of healthcare resources : Results of the Scandinavian Simvastatin Survival Study.

    Article - En anglais

    Background Advanccs in the treatment of cardiovascular disease have increased costs ; annual cardiovascular healthcare expenditure in the United States currently exceeds $100 billion.

    Physicians and third-party payers need to assess the economic impact of treatments that reduce cardiovascular morbidity and mortality.

    Methods and Results The Scandinavian Simvastatin Survival Study is a randomized, double-blind, placebo-controlled trial in which simvastatin reduced the risk of death by 30% (P=0003) over the median follow-up period of 5.4 years in patients with previous myocardial infarction or stable angina pectoris as a result of a 42% reduction in the risk of coronary deaths (P=00001).

    In the present report, data prospectively collected from hospital admissions were analyzed to evaluate the impact of simvastatin on healthcare resource use and perform a cost-minimization analysis.

    In the placebo group (n=2223), there were 1905 hospitalizations (average duration, 7.9 days) for acute cardiovascular events or coronary revascularization procedures among 937 patients, whereas in the simvastatin group (n=2221), there were 1403 such hospitalizations (average duration, 7.1 days) among 720 patients (all differences, P<. 0001).

    The corresponding number of hospital days was 15 089 and 9951 in the two groups, respectively (34% reduction, P<. 0001).

    In the United States, the resulting reduction in hospitalization costs over the 5.4 years of the trial would he $3872 per ...

    Mots-clés Pascal : Athérosclérose, Cardiopathie coronaire, Cholestérolémie, Simvastatine, Economie santé, Hospitalisation, Analyse avantage coût, Pays Scandinaves, Europe, Traitement, Survie, Homme, Hypolipémiant, Appareil circulatoire pathologie, Vaisseau sanguin pathologie, Analyse biochimique, Chimiothérapie, Evaluation

    Mots-clés Pascal anglais : Atherosclerosis, Coronary heart disease, Cholesterolemia, Health economy, Hospitalization, Cost benefit analysis, Scandinavia, Europe, Treatment, Survival, Human, Antilipemic agent, Cardiovascular disease, Vascular disease, Biochemical analysis, Chemotherapy, Evaluation

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 96-0284246

    Code Inist : 002B02N. Création : 199608.